- Details
- Alicia Morgans hosts Shankar Siva who sheds light on the innovative use of Stereotactic Ablative Body Radiotherapy (SBRT/SABR) for treating oligometastatic kidney cancer. Dr. Siva outlines the three clinical scenarios where SABR is employed: de novo oligometastatic disease, oligoprogressive disease during systemic therapy, and in certain de novo metastatic settings. He emphasizes the effectiveness...
|
- Details
- Dan George discusses the CheckMate-67T study with Saby George, a phase three trial comparing intravenous and subcutaneous administration of nivolumab in treatment-refractory kidney cancer patients. Conducted across 73 centers in 17 countries, this trial aimed to assess if subcutaneous nivolumab could match the systemic effects of its IV counterpart. Meeting its co-primary pharmacokinetic endpoints...
|
- Details
- Pedro Barata and Nizar Tannir delve into the eight-year results of the CheckMate-214 trial, showcasing the sustained efficacy of ipilimumab and nivolumab (ipi/nivo) in advanced renal cell carcinoma (RCC). Dr. Tannir highlights the treatment's enduring hazard ratio and significant mortality risk reduction, emphasizing the notable longevity and durability of patient responses. Their conversation nav...
|
- Details
- Dimitrios Makrakis presents a significant meta-analysis exploring the role of cytoreductive nephrectomy in patients undergoing immune checkpoint inhibition for metastatic renal cell carcinoma. This study, a substantial effort involving 2,319 patients, sought to address the gap in understanding post-CARMENA, focusing on outcomes in the era of immune checkpoint inhibitors. The analysis, utilizing in...
|
- Details
- Pedro Barata and María Bourlon discuss the CheckMate 9ER trial's 55-month follow-up, revealing the enduring benefits of cabozantinib plus nivolumab over sunitinib in untreated advanced renal cell carcinoma. The trial highlights significant advancements in overall survival, progression-free survival, and response rates, alongside improved quality of life for patients. Dr. Bourlon emphasizes the tri...
|
- Details
- Pedro Barata engages in a discussion with Martin Voss about volrustomig, a novel PD-1/CTLA-4 bispecific antibody for advanced clear cell RCC. Dr. Voss provides an overview of volrustomig, highlighting its unique ability to inhibit PD-1 and selectively bind CTLA-4 on cells co-expressing both receptors, aiming for targeted action in the tumor microenvironment. He reviews the dose-finding study's pro...
|
- Details
- Pedro Barata engages in a conversation with Dan George about developments in kidney cancer treatments from the ESMO conference. Their discussion centers on the EVEREST trial, which investigates the use of the mTOR inhibitor everolimus in an adjuvant setting for high-risk kidney cancer patients post-nephrectomy. Dr. George emphasizes the significance of targeting high-risk patients, particularly th...
|
- Details
- Neeraj Agarwal discusses the phase two LITESPARK-013 trial exploring the efficacy of belzutifan, a hypoxia-inducible transcription factor 2 alpha inhibitor, in treating metastatic renal cell carcinoma. The trial compares two doses of belzutifan (120 milligrams and 200 milligrams daily) in patients who have progressed on PD-1 axis inhibitors. The primary endpoint is the objective response rate, wit...
|
- Details
- Pedro Barata speaks with Kathryn Beckermann regarding a groundbreaking Phase I/IIb trial she presented at ASCO. This trial explored the use of a new AXL inhibitor, in conjunction with cabozantinib and nivolumab, for advanced Renal Cell Carcinoma (RCC). Dr. Beckermann elucidates the rationale behind targeting the Gas6 AXL pathway, known for its upregulation in kidney cancer and its role as a resist...
|
- Details
- Pedro Barata and Ritesh Kotecha discuss a study examining genetic ancestry and molecular correlations in kidney cancer patients. Dr. Kotecha outlines the comprehensive approach taken to genomic testing, including both somatic and germline testing. Highlighting their cohort of over 900 patients, they discuss the collection and analysis of genomic information. Dr. Kotecha elucidates their use of gen...
|
